内镜鼻窦手术治疗变应性真菌性鼻窦炎疗效的系统评价与Meta分析
该系统评价与Meta分析纳入31项研究共1474例变应性真菌性鼻窦炎(AFRS)患者,评估内镜鼻窦手术(ESS)的疗效。ESS显著改善鼻窦生活质量(SNOT-22评分合并降低23.37分,95%CI 18.71-28.02),总体复发率为31%(95%CI 25%-38%),翻修手术率为19%(95%CI 14%-25%)。术后口服伊曲康唑与未使用者相比,复发率(30.7% vs 31.1%,P=.957)和翻修率(18.2% vs 20.3%,P=.643)均无显著差异。
要点
- ESS可显著改善AFRS患者术后鼻窦生活质量,SNOT-22评分合并降低23.37分。
- AFRS术后总体复发率为31%,翻修手术率为19%。
- 术后口服伊曲康唑未显著降低复发率或翻修手术率。
核心结论
- ESS可显著改善AFRS患者术后生活质量,但复发率(31%)和翻修率(19%)仍较高。
- 术后口服伊曲康唑与复发率或翻修率降低无关。
- 需进一步高质量研究明确最佳术后辅助治疗以减少复发。
研究设计与样本
- 纳入31项报告AFRS患者ESS术后结局和复发的研究,共1474例患者。
- 随访时间1.5至32.5个月(均值13.7个月),术后药物治疗存在较大异质性。
主要发现
- 总体复发率为31%(95%CI 25%-38%)。
- ESS翻修手术率为19%(95%CI 14%-25%)。
- SNOT-22评分合并降低23.37分(95%CI 18.71-28.02)。
- 术后口服伊曲康唑组与非伊曲康唑组复发率分别为30.7%和31.1%(P=.957)。
- 术后口服伊曲康唑组与非伊曲康唑组翻修手术率分别为18.2%和20.3%(P=.643)。
临床怎么用
- ESS可作为AFRS改善生活质量的有效治疗手段,但应告知患者术后复发和翻修风险较高。
- 术后口服伊曲康唑不应常规用于降低复发或翻修风险,需个体化评估。
局限性
- 随访时间范围宽(1.5至32.5个月),术后药物治疗异质性大。
- 需进一步高质量研究明确最佳术后辅助治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Endoscopic sinus surgery (ESS) plays a central role in the management of allergic fungal rhinosinusitis (AFRS); however, outcomes vary across studies. The goal of this study is to systematically review and synthesize evidence on the outcomes of ESS in patients with AFRS. DATA SOURCES: PubMed, Scopus, Web of Science, and the Cochrane Central Register of Controlled Trials. REVIEW METHODS: A systematic search of the literature was conducted from inception to October 2025, following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Studies reporting postoperative outcomes and recurrence following ESS in AFRS were included. RESULTS: Thirty-one studies encompassing 1474 AFRS patients were analyzed. Follow-up durations ranged from 1.5 to 32.5 months (mean = 13.7 months), with substantial variability in postoperative medical therapy. The overall disease recurrence rate was 31% (95% CI, 25%-38%), and the pooled ESS revision rate was 19% (95% CI, 14%-25%). ESS significantly improved sinonasal quality of life, with a pooled reduction in 22-item sinonasal outcome test (SNOT-22) score of 23.37 points (95% CI, 18.71-28.02). Postoperative oral itraconazole use was not associated with a lower recurrence rate (30.7% vs 31.1%, P = .957), nor a lower surgical revision rate (18.2% vs 20.3%, P = .643). CONCLUSION: ESS substantially improves postoperative quality of life in AFRS, with an overall recurrence rate of 31% and surgical revision rate of 19%. Further high-quality studies are needed to define optimal postoperative adjuvant therapy to minimize recurrence and enhance long-term outcomes.
引用
- Kais A, Kfouri J, Sedaghat AR, et al. Efficacy of Endoscopic Sinus Surgery for Allergic Fungal Rhinosinusitis: A Systematic Review With Meta-analysis. Otolaryngol Head Neck Surg. 2026. PMID: 42765459. doi:10.1002/ohn.70439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。